India–UK Trade Deal and API Exports: What Buyers and Exporters Need to Know

The India–UK trade agreement, formally the Comprehensive Economic and Trade Agreement (CETA), entered into force on July 15, 2026. For pharmaceutical companies, the headline is easy to repeat: duty-free or reduced-duty access to the UK market. For anyone sourcing or exporting active pharmaceutical ingredients, the real questions are narrower. This guide looks at what the deal means for India UK FTA API exports, what the published numbers show, and what buyers and exporters should check before assuming a tariff benefit.

What the Deal Does, in Brief

• In force: The UK–India agreement entered into force on July 15, 2026.
• Tariffs: The Pharmaceutical Export Promotion Council (Pharmexcil) described the deal as granting duty-free access to almost all Indian exports to the UK, with pharmaceuticals named as an expected beneficiary. A legal-sector analysis describes pharma tariffs as “expected to reduce significantly” and does not list which product lines get zero duty or whether there is a phase-in schedule.
• APIs specifically: In the sources we reviewed, we did not find a published tariff schedule for APIs. Buyers should confirm the duty treatment of their exact product and HS code, rather than assume.

What the Numbers Show

Two cautions on reading these figures. The US$ 981 million number is a projection, not a reported result. And by our own calculation from the two reported figures, APIs and bulk drugs were roughly 8% of exports to the UK in FY2025-26. That makes the UK a modest but real market for API suppliers, and one where formulations dominate.

Why API Buyers and Exporters Should Pay Attention

Even a modest API market can matter if the rules change in your favour. Three things are worth watching:

1. Landed cost. : If a duty that previously applied to your product is removed or reduced, it changes your landed cost. Confirm whether this applies to your product before you build it into a quote.
2. Competitiveness of Indian generics. : Pharmexcil expects duty-free access to benefit generic drug manufacturers. If Indian-made finished generics become more competitive in the UK, UK-bound formulators may need more reliable API supply.
3. Collaboration. : Pharmexcil also expects more collaboration between Indian and British companies in research and healthcare, which can lead to new sourcing relationships.

The Catch: Preferential Duty Is Not Automatic

This is the most important point for exporters and importers.

Rules of origin. Preferential treatment depends on meeting the agreement’s rules of origin, which determine whether goods are sufficiently produced or processed in India. A UK customs adviser notes that:

• Claims need evidence that the goods qualify, so importers should obtain appropriate origin declarations from suppliers.
• Supporting records should be kept for customs audit purposes.
• Preference claims must be declared correctly on customs entries.
• If valid origin evidence is not provided, duties may become payable retrospectively.

A legal analysis adds that origin analysis for pharmaceuticals may look at API sourcing, imported intermediates, manufacturing in India, substantial transformation, and documentation. For APIs, this is a good reason to ask where the starting materials and intermediates come from.

Zero duty is not zero regulatory barriers. The UK regulator, the MHRA, still governs medicines. The same legal analysis lists requirements that may apply, including marketing authorisations, GMP, quality systems, pharmacovigilance, labelling and stability data. The agreement removes tariffs, not these requirements.

What UK-Bound Buyers Should Ask Their API Supplier

1. Can you provide an origin declaration for this API? Ask what documentation they can issue, and keep records for audits.
2. Where do the starting materials and intermediates come from? This affects the origin analysis. A supplier that makes its own intermediates in India usually has a clearer story, but confirm this with your customs adviser.
3. Which pharmacopoeial grade do you supply? The British Pharmacopoeia (BP) is the UK standard, so confirm that BP-grade documentation is available for your product. See our guide to API grades: USP vs BP vs EP vs IP.
4. What GMP evidence can you provide for the exact production site? Facility-level certificates matter for UK registrations.
5. Can you provide DMF or equivalent documentation support? Ask what is available for your product and market.
6. What are your lead times and MOQs? Compare against your planning needs.

What Indian API Exporters Should Do Now

• Get origin documentation in order. Work out how your products qualify under the rules of origin, and prepare declarations before customers ask.
• Map your supply chain. Know which starting materials and intermediates are made in India and which are imported.
• Check pharmacopoeial and regulatory readiness. BP-grade documentation and GMP evidence for the specific facility are the basics UK buyers look for.
• Talk to your customs adviser. Don’t advertise a duty benefit until you’ve confirmed it for your HS code.
• Treat the UK as part of a wider strategy. The UK sits alongside other markets, including the EU and emerging markets, as Indian exporters diversify beyond the US. See our post on the US generic drug tariff plan.

Chemox Pharma and the UK Market

Chemox Pharma is a WHO-GMP certified API and intermediates manufacturer in Dahej, Gujarat. We manufacture APIs and intermediates ourselves, and our team can discuss the grade documentation, GMP evidence and origin information available for the product you need. Grade availability depends on the specific API, so please confirm this with us before placing an order.

Request a Quote for UK-Bound Supply

If you are sourcing API for the UK market and want to discuss documentation, lead times and current availability, get in touch with Chemox Pharma for a quote and documentation review.

FAQs

Q: When did the India–UK trade agreement come into force?

The UK–India Comprehensive Economic and Trade Agreement (CETA) entered into force on July 15, 2026.

Q: Are APIs duty-free under the India–UK FTA?

Pharmexcil describes duty-free access for almost all Indian exports, and pharmaceuticals are named as an expected beneficiary. In the sources we reviewed, we did not find a published tariff schedule for APIs specifically, so confirm the treatment of your product and HS code with a customs adviser.

Q: How big are Indian API exports to the UK?

APIs and bulk drugs to the UK were US$ 72.66 million in FY2025-26, according to Pharmexcil data reported by BioSpectrum. Drug formulations and biologicals made up 89.54% of Indian pharma exports to the UK.

Q: Do importers automatically get the lower duty?

No. Preferential treatment depends on meeting the rules of origin and providing valid origin evidence. If valid evidence is not provided, duties may become payable retrospectively.

Q: Does the FTA change UK regulatory requirements for APIs and medicines?

No. The MHRA remains the regulator, and requirements such as GMP, quality systems and marketing authorisations still apply.